This phase II Pediatric MATCH trial studies how well ensartinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with ALK or ROS1 genomic alterations that have come back (recurrent) or do not respond to treatment (refractory) and have spread to other places in the body (advanced). Ensartinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Principal Investigator
Anne-Marie Langevin
Jaclyn Hung
+1 (210) 450-5358
hungj@uthscsa.edu
Arm | Description | Intervention |
---|---|---|
Treatment (ensartinib) | Patients receive ensartinib PO QD on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity. | Given PO Other names:
Correlative studies Correlative studies |